{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:11:18Z","timestamp":1793866278330,"version":"4.6.1"},"reference-count":168,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jhep.2026.03.038","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:06:15Z","timestamp":1779840375000},"page":"583-602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis"],"prefix":"10.1016","volume":"85","author":[{"given":"Cynthia","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Lleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrielly","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Scaravaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Bowlus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia A.","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyn J.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Villamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femi","family":"Adekunle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Belous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Bittermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Cazzagon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Culver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Cure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Doverskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Leburgue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Carlota","family":"Londono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Lowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Mells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Meloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Michell-Thain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo J.","family":"Montano-Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nitschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deven","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Sleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Span","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Wendy","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"van Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Thorburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Troke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Weltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"10457","key":"10.1016\/j.jhep.2026.03.038_bib3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary biliary cholangitis","volume":"404","author":"Tanaka","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.038_bib4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.038_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.cgh.2017.09.062","article-title":"Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists","volume":"16","author":"Webb","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis","volume":"29","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib8","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.038_bib10","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2026.03.038_bib11","author":"European Medicines Agency"},{"key":"10.1016\/j.jhep.2026.03.038_bib12","series-title":"Center for drug evaluation and research","article-title":"Approval letter \u2013 OCALIVA (obeticholic acid) tablets, NDA 207999, accelerated approval","author":"U.S. Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.jhep.2026.03.038_bib13","series-title":"Committee for medicinal products for human use (CHMP)","article-title":"Summary of opinion (initial authorisation): Ocaliva (obeticholic acid)","author":"European Medicines Agency","year":"2016"},{"key":"10.1016\/j.jhep.2026.03.038_bib14","series-title":"Center for drug evaluation and research","article-title":"Approval letter \u2013 livdelzi (seladelpar) capsules, NDA 217899, accelerated approval","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"10.1016\/j.jhep.2026.03.038_bib15","series-title":"Committee for medicinal products for human use (CHMP)","article-title":"Summary of opinion (initial authorisation): seladelpar Gilead (seladelpar)","author":"European Medicines Agency","year":"2024"},{"key":"10.1016\/j.jhep.2026.03.038_bib16","series-title":"Center for drug evaluation and research","article-title":"Approval letter \u2013 iqirvo (elafibranor) tablets, NDA 218860, accelerated approval","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"10.1016\/j.jhep.2026.03.038_bib17","series-title":"Committee for medicinal products for human use (CHMP)","article-title":"Summary of opinion (initial authorisation): iqirvo (elafibranor)","author":"European Medicines Agency","year":"2024"},{"key":"10.1016\/j.jhep.2026.03.038_bib18","series-title":"Center for drug evaluation and research (CDER) CfBEaRC","article-title":"Demonstrating substantial evidence of effectiveness for human drug and biological products: guidance for industry (draft guidance)","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"10.1016\/j.jhep.2026.03.038_bib19","series-title":"Center for drug evaluation and research (CDER) CfBEaRC, oncology center of excellence (OCE)","article-title":"Demonstrating substantial evidence of effectiveness with one adequate and well-controlled clinical investigation and confirmatory evidence: guidance for industry (draft guidance)","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"10.1016\/j.jhep.2026.03.038_bib20","series-title":"Oncology center of excellence","article-title":"Accelerated approval and considerations for determining whether a confirmatory trial is underway: guidance for industry (draft guidance)","author":"U.S. Food and Drug Administration","year":"2025"},{"issue":"23","key":"10.1016\/j.jhep.2026.03.038_bib21","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib22","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib23","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep.30552","article-title":"Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis","volume":"70","author":"Honda","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.038_bib24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.14309\/ajg.0000000000003029","article-title":"COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls","volume":"120","author":"Kowdley","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib25","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2022.08.054","article-title":"Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls","volume":"163","author":"Murillo Perez","year":"2022","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.038_bib26","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/apt.70378","article-title":"Non-response to obeticholic acid is associated with heightened risks of developing clinical events in primary biliary cholangitis","volume":"63","author":"Abbas","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.03.038_bib27","series-title":"FDA adds Boxed Warning to highlight correct dosing of Ocaliva (obeticholic acid) for patients with a rare chronic liver disease","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.jhep.2026.03.038_bib28","series-title":"Due to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis","author":"U.S. Food and Drug Administration","year":"2021"},{"key":"10.1016\/j.jhep.2026.03.038_bib29","series-title":"Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"10.1016\/j.jhep.2026.03.038_bib30","series-title":"(CHMP) CfMPfHU","article-title":"Revocation of conditional marketing authorisation for Ocaliva (obeticholic acid)","author":"European Medicines Agency","year":"2024"},{"key":"10.1016\/j.jhep.2026.03.038_bib31","series-title":"Intercept announces voluntary withdrawal of OCALIVA\u00ae for primary biliary cholangitis (PBC) from the US market; US clinical trials involving obeticholic acid placed on clinical hold","author":"Intercept Pharmaceuticals","year":"2025"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020476","article-title":"Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review","volume":"6","author":"Boulkedid","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.038_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jhep.2026.03.038_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2021.101401","article-title":"Preparing, conducting, and analyzing Delphi surveys: cross-disciplinary practices, new directions, and advancements","volume":"8","author":"Beiderbeck","year":"2021","journal-title":"MethodsX"},{"key":"10.1016\/j.jhep.2026.03.038_bib35","unstructured":"Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation."},{"key":"10.1016\/j.jhep.2026.03.038_bib36","series-title":"The guidelines manual. Chapter 9: developing and wording guideline recommendations","author":"National Institute for Health and Care Excellence","year":"2012"},{"issue":"25","key":"10.1016\/j.jhep.2026.03.038_bib37","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.038_bib38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.038_bib39","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate end points in clinical trials: are we being misled?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2026.03.038_bib40","series-title":"Surrogate endpoint resources for drug and biologic development","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.jhep.2026.03.038_bib41","series-title":"Committee for medicinal products for human use (CHMP)","article-title":"Guideline on clinical trials in small populations","author":"European Medicines Agency","year":"2006"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/hep.1840060307","article-title":"The mechanism of elevated alkaline phosphatase activity after bile duct ligation in the rat","volume":"6","author":"Seetharam","year":"1986","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-8981(96)06438-8","article-title":"Physicochemical and pathophysiological factors in the release of membrane-bound alkaline phosphatase from cells","volume":"257","author":"Moss","year":"1997","journal-title":"Clin Chim Acta"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib44","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.27715","article-title":"Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation","volume":"61","author":"Poupon","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.038_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104068","article-title":"The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: a cohort study","volume":"80","author":"Jones","year":"2022","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib46","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.038_bib47","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib48","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.038_bib49","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.038_bib50","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12016-017-8656-x","article-title":"Geoepidemiology of primary biliary cholangitis: lessons from Switzerland","volume":"54","author":"Terziroli Beretta-Piccoli","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.038_bib51","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/apt.15533","article-title":"Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response","volume":"50","author":"Murillo Perez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.038_bib52","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should Be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.038_bib53","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.cgh.2020.08.006","article-title":"Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis","volume":"19","author":"Gerussi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.038_bib54","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MCG.0000000000001433","article-title":"Liver stiffness measured by either magnetic resonance or transient elastography is associated with liver fibrosis and is an independent predictor of outcomes among patients with primary biliary cholangitis","volume":"55","author":"Osman","year":"2021","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.038_bib55","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/MEG.0000000000002216","article-title":"Simplified 6-month prediction scores for primary biliary cholangitis patients treated with ursodeoxycholic acid","volume":"34","author":"Pinyopornpanish","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.038_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(22)01031-5","article-title":"THU482 - should we seek complete liver tests normalization in primary biliary cholangitis? Data from ColHai registry","volume":"77","author":"D\u00edaz-Gonz\u00e1lez","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.038_bib57","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1016\/S0168-8278(23)01050-4","article-title":"WED-293 - prognostic value of serum ALP levels during additional treatment in Japanese patients with primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate","volume":"78","author":"Takeuchi","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?","volume":"79","author":"Corpechot","year":"2024","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.038_bib59","article-title":"Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis","volume":"6","author":"Roberts","year":"2024","journal-title":"JHEP Rep"},{"issue":"11","key":"10.1016\/j.jhep.2026.03.038_bib60","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/apt.70120","article-title":"Longitudinal relationship between elevated liver biochemical tests and negative clinical outcomes in primary biliary cholangitis: a population-based study","volume":"61","author":"Kowdley","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.03.038_bib61","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/S0168-8278(25)00960-2","article-title":"THU-272 Appraising improvement in prediction of clinical outcomes based on different response criteria and liver stiffness measurements in patients with primary biliary cholangitis treated with second-line therapies","volume":"82","author":"de Vincentis","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.038_bib62","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1016\/S0168-8278(25)00979-1","article-title":"THU-296 Evaluation of response to Ursodeoxycholic acid (UDCA) in a nationwide population with primary biliary cholangitis","volume":"82","author":"Werner","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.038_bib63","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0168-8278(25)00401-5","article-title":"OS-086 Evaluation of the response criteria following second-line treatment with bezafibrate in patients with primary biliary cholangitis","volume":"82","author":"Hern\u00e1ndez-\u00c9vole","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.038_bib64","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S0168-8278(25)00403-9","article-title":"OS-088 FiOCA study: comparative analysis of transplant-free survival in primary biliary cholangitis patients treated with obeticholic acid or fibrates","volume":"82","author":"Ronca","year":"2025","journal-title":"J Hepatol"},{"issue":"20","key":"10.1016\/j.jhep.2026.03.038_bib65","article-title":"Obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jhep.2026.03.038_bib66","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jhep.2026.03.038_bib67","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib68","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00535-014-0998-z","article-title":"Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA","volume":"50","author":"Tanaka","year":"2015","journal-title":"J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.038_bib69","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1872-034X.2011.00782.x","article-title":"Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis","volume":"41","author":"Azemoto","year":"2011","journal-title":"Hepatol Res"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib70","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/liv.14688","article-title":"Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis","volume":"41","author":"Haldar","year":"2021","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.jhep.2026.03.038_bib71","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/apt.17226","article-title":"Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid","volume":"56","author":"de Veer","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.038_bib72","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2025.09.024","article-title":"Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis","volume":"84","author":"Wong","year":"2026","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib73","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.038_bib74","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s00535-013-0903-1","article-title":"Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients","volume":"49","author":"Lammert","year":"2014","journal-title":"J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.038_bib75","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.038_bib76","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.14309\/ajg.0000000000000290","article-title":"Validation of risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangitis","volume":"114","author":"Efe","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"1S Suppl 1","key":"10.1016\/j.jhep.2026.03.038_bib77","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1097\/MEG.0000000000002011","article-title":"Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium","volume":"33","author":"Pariente","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.038_bib78","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.14309\/ajg.0000000000002128","article-title":"Ursodeoxycholic acid treatment-induced GLOBE score changes are associated with liver transplantation-free survival in patients with primary biliary cholangitis","volume":"118","author":"de Veer","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib79","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12072-024-10743-w","article-title":"Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment","volume":"19","author":"Ding","year":"2025","journal-title":"Hepatol Int"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.038_bib80","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.14309\/ajg.0000000000001285","article-title":"A comparison of prognostic scores (Mayo, UK-PBC, and GLOBE) in primary biliary cholangitis","volume":"116","author":"Goet","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib81","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cgh.2019.08.013","article-title":"Factors associated with progression and outcomes of early stage primary biliary cholangitis","volume":"18","author":"Gatselis","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.038_bib82","series-title":"Committee for medicinal products for human use (CHMP)","article-title":"Reflection paper on regulatory requirements for the development of medicinal products for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC)","author":"European Medicines Agency","year":"2023"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib83","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib84","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2026.03.038_bib85","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.cgh.2024.06.035","article-title":"Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis","volume":"22","author":"Lam","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib86","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12072-023-10587-w","article-title":"Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria","volume":"18","author":"Ding","year":"2024","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.038_bib87","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/hep.22517","article-title":"Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay","volume":"48","author":"Mayo","year":"2008","journal-title":"Hepatology"},{"issue":"39","key":"10.1016\/j.jhep.2026.03.038_bib88","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027403","article-title":"Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis","volume":"100","author":"Fujinaga","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib89","first-page":"25","article-title":"Real-world evidence: a primer","volume":"37","author":"Dang","year":"2023","journal-title":"Pharmaceut Med"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70117","article-title":"Real-world data and real-world evidence in regulatory decision making: report summary from the council for international organizations of medical Sciences (CIOMS) working group XIII","volume":"34","author":"Hennessy","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jhep.2026.03.038_bib91","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.jhep.2026.03.038_bib92","series-title":"Data analytics and methods task force R-WETT-R","article-title":"Real-world evidence provided by EMA: support for regulatory decision-making","author":"European Medicines Agency","year":"2024"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.038_bib93","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/HEP.0000000000000864","article-title":"Primary biliary cholangitis drug evaluation and regulatory approval: where do we go from here?","volume":"80","author":"Jones","year":"2024","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.038_bib94","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/cpt.2213","article-title":"Defining clinically relevant target populations using real-world data to guide the design of representative antidiabetic drug trials","volume":"109","author":"Pradhan","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hec.4903","article-title":"Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations","volume":"34","author":"Lugo-Palacios","year":"2025","journal-title":"Health Econ"},{"key":"10.1016\/j.jhep.2026.03.038_bib96","series-title":"Center for drug evaluation and research; center for biologics evaluation and research; oncology center of excellence","article-title":"Real-world data: assessing registries to support regulatory decision-making for drug and biological products. Guidance for industry","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"10.1016\/j.jhep.2026.03.038_bib97","series-title":"HMA-EMA joint big data steering group","article-title":"Data quality framework for EU medicines regulation","author":"European Medicines Agency","year":"2023"},{"key":"10.1016\/j.jhep.2026.03.038_bib98","series-title":"Committee for medicinal products for human use (CHMP) MWP","article-title":"Data quality framework for EU medicines regulation: application to real-world data","author":"European Medicines Agency","year":"2024"},{"key":"10.1016\/j.jhep.2026.03.038_bib99","series-title":"Framework for FDA's real-world evidence Program","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.jhep.2026.03.038_bib100","series-title":"Guideline on registry-based studies","author":"European Medicines Agency","year":"2021"},{"key":"10.1016\/j.jhep.2026.03.038_bib101","series-title":"Center for drug evaluation and research; center for biologics evaluation and research; oncology center of excellence","article-title":"Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products. Guidance for industry","author":"U.S. Food and Drug Administration","year":"2023"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.038_bib102","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/hep4.1173","article-title":"A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale","volume":"2","author":"Levy","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2026.03.038_bib103","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2147\/CLEP.S262558","article-title":"Validity of an automated algorithm to identify cirrhosis using electronic health records in patients with primary biliary cholangitis","volume":"12","author":"Lu","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.038_bib104","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/liv.15592","article-title":"Optimizing therapy in primary biliary cholangitis: alkaline phosphatase at six months identifies one-year non-responders and predicts survival","volume":"43","author":"Murillo Perez","year":"2023","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.038_bib105","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000677","article-title":"A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providers","volume":"9","author":"Levy","year":"2025","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.038_bib106","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/1062860606288774","article-title":"Challenges of using medical insurance claims data for utilization analysis","volume":"21","author":"Tyree","year":"2006","journal-title":"Am J Med Qual"},{"key":"10.1016\/j.jhep.2026.03.038_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2026.03.038_bib108","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1111\/j.1524-4733.2007.00275.x","article-title":"Patient-reported outcomes to support medical product labeling claims: FDA perspective","volume":"10","author":"Patrick","year":"2007","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.038_bib109","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/pds.1926","article-title":"A basic study design for expedited safety signal evaluation based on electronic healthcare data","volume":"19","author":"Schneeweiss","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"10.1016\/j.jhep.2026.03.038_bib110","article-title":"Effects of electronic health record implementation and barriers to adoption and use: a scoping review and qualitative analysis of the content","volume":"10","author":"Tsai","year":"2020","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jhep.2026.03.038_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.038_bib112","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/01.ede.0000222026.42077.ee","article-title":"Instrumental variable analysis of secondary pharmacoepidemiologic data","volume":"17","author":"Brookhart","year":"2006","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib113","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1357","article-title":"Immortal time bias in observational studies of drug effects","volume":"16","author":"Suissa","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jhep.2026.03.038_bib114","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib115","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/ije\/dyi060","article-title":"Proper interpretation of non-differential misclassification effects: expectations vs observations","volume":"34","author":"Jurek","year":"2005","journal-title":"Int J Epidemiol"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib116","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/HEP.0000000000001174","article-title":"Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): a trial emulation study design","volume":"81","author":"Brookhart","year":"2025","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib117","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1097\/HEP.0000000000001198","article-title":"Obeticholic acid as second-line therapy for primary biliary cholangitis: does target trial emulation solve the issue?","volume":"81","author":"Bittermann","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.038_bib118","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/1536867X0400400403","article-title":"Controlling for time-dependent confounding using marginal structural models","volume":"4","author":"Fewell","year":"2004","journal-title":"Stata J"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib119","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1742-7843.2006.pto_293.x","article-title":"Indications for propensity scores and review of their use in pharmacoepidemiology","volume":"98","author":"Glynn","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.jhep.2026.03.038_bib121","series-title":"Applying quantitative bias analysis to epidemiologic data","author":"Lash","year":"2009"},{"key":"10.1016\/j.jhep.2026.03.038_bib122","doi-asserted-by":"crossref","first-page":"f3345","DOI":"10.1136\/bmj.f3345","article-title":"Selection bias versus allocation bias","volume":"346","author":"Sedgwick","year":"2013","journal-title":"BMJ"},{"issue":"7972","key":"10.1016\/j.jhep.2026.03.038_bib123","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41586-023-06291-2","article-title":"Large language models encode clinical knowledge","volume":"620","author":"Singhal","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2026.03.038_bib124","series-title":"Committee for medicinal products for human use (CHMP) MWPM","article-title":"Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence for regulatory purposes","author":"European Medicines Agency","year":"2025"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cpt.2453","article-title":"The friends of cancer research real-world data collaboration pilot 2.0: methodological recommendations from oncology case studies","volume":"111","author":"Rivera","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib126","article-title":"The role of patient-reported outcomes in a patient-centered care model for managing chronic liver diseases","volume":"23","author":"Verma","year":"2024","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.038_bib127","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/hep4.1567","article-title":"A systematic review of patient-reported outcomes in primary biliary cholangitis and primary sclerosing cholangitis","volume":"4","author":"Kim","year":"2020","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.038_bib128","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.cgh.2020.06.025","article-title":"Effects of primary biliary cholangitis on quality of life and health care costs in the United Kingdom","volume":"19","author":"Rice","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2026.03.038_bib129","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1136\/gut.2005.065862","article-title":"Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis","volume":"54","author":"Jacoby","year":"2005","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib131","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"5 Suppl 1","key":"10.1016\/j.jhep.2026.03.038_bib132","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/01.mlr.0000254567.79743.e2","article-title":"Evaluation of item candidates: the PROMIS qualitative item review","volume":"45","author":"DeWalt","year":"2007","journal-title":"Med Care"},{"issue":"9 Suppl","key":"10.1016\/j.jhep.2026.03.038_bib133","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.apmr.2009.10.035","article-title":"Measuring participation: the patient-reported outcomes measurement information system experience","volume":"91","author":"Bode","year":"2010","journal-title":"Arch Phys Med Rehabil"},{"issue":"11","key":"10.1016\/j.jhep.2026.03.038_bib134","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1038\/s41591-025-03906-1","article-title":"Patient-reported outcome measures add value as clinical trial endpoints","volume":"31","author":"Crossnohere","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib135","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41687-018-0090-1","article-title":"Development and adaptation of patient-reported outcome measures for patients who experience itch associated with primary biliary cholangitis","volume":"3","author":"Martin","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.jhep.2026.03.038_bib136","series-title":"Committee for medicinal products for human use (CHMP); pharmacovigilance risk assessment committee (PRAC)","article-title":"Reflection paper on patient experience data","author":"European Medicines Agency","year":"2025"},{"key":"10.1016\/j.jhep.2026.03.038_bib137","series-title":"Center for drug evaluation and research; center for biologics evaluation and research; center for devices and radiological health","article-title":"Patient-reported outcome measures: use in medical product development to support labeling claims","author":"U.S. Food and Drug Administration","year":"2009"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.038_bib138","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11136-004-0705-2","article-title":"Estimating clinically significant differences in quality of life outcomes","volume":"14","author":"Wyrwich","year":"2005","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib139","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s41687-021-00336-8","article-title":"Measuring health-related quality of life in patients with rare disease","volume":"5","author":"Lenderking","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.jhep.2026.03.038_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(25)01017-7","article-title":"THU-341 Implementation of a clinical global impression severity scale for primary biliary cirrhosis: results of a hepatologist focussed training programme","volume":"82","author":"Hussain","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.038_bib141","first-page":"S335","article-title":"THU-340 Validation of the clinical global impression severity scale for primary biliary cholangitis: a clinical trials outcome tool","volume":"82","author":"Hussain","year":"2025","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib142","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/gut.2007.139303","article-title":"Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance","volume":"57","author":"Newton","year":"2008","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.038_bib143","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/AJP.0b013e31820485db","article-title":"Nightly analyses of subjective and objective (actigraphy) measures of sleep in fibromyalgia syndrome: what accounts for the discrepancy?","volume":"27","author":"Okifuji","year":"2011","journal-title":"Clin J Pain"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.038_bib144","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2005.12.012","article-title":"Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure","volume":"44","author":"Newton","year":"2006","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.038_bib145","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/hep.23683","article-title":"The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice","volume":"52","author":"Al-Harthy","year":"2010","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.038_bib146","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1007\/s10620-020-06502-0","article-title":"Understanding fatigue in primary biliary cholangitis","volume":"66","author":"Phaw","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.038_bib147","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/qjmed\/hcn043","article-title":"An integrated care pathway improves quality of life in Primary Biliary Cirrhosis","volume":"101","author":"Jones","year":"2008","journal-title":"QJM"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib148","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib149","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.038_bib150","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/apt.13794","article-title":"The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis","volume":"44","author":"Dyson","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib151","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1097\/HEP.0000000000000508","article-title":"Time to embrace PROMIS-29 as the standard health-related quality of life instrument for patients with cirrhosis","volume":"78","author":"Tapper","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib152","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000635","article-title":"Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: data from the GLIMMER study","volume":"9","author":"Smith","year":"2025","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib153","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","article-title":"Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis","volume":"68","author":"Mayo","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.038_bib154","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib155","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s13023-025-03798-x","article-title":"Psychometric validation of the Worst Itch Numerical Rating Scale (WI-NRS) and other patient-reported outcome measures for assessing severity and impact of pruritus in patients with primary biliary cholangitis","volume":"20","author":"Gelhorn","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib156","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40271-017-0266-4","article-title":"Development of a novel tool to assess the impact of itching in pediatric cholestasis","volume":"11","author":"Kamath","year":"2018","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib157","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2468-1253(25)00192-X","article-title":"Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Hirschfield","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.038_bib158","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib159","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/15402002.2012.636266","article-title":"Development of short forms from the PROMIS\u2122 sleep disturbance and Sleep-Related Impairment item banks","volume":"10","author":"Yu","year":"2011","journal-title":"Behav Sleep Med"},{"key":"10.1016\/j.jhep.2026.03.038_bib160","first-page":"1","article-title":"PBC-HOPE: a randomized controlled trial of hypnosis and psychoeducation in women with primary biliary cholangitis and fatigue","author":"Untas","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib161","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/hep.21609","article-title":"Population prevalence and symptom associations of autonomic dysfunction in primary biliary cirrhosis","volume":"45","author":"Newton","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib162","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S2468-1253(25)00257-2","article-title":"Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases","volume":"11","author":"Koc","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2026.03.038_bib163","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/clinids\/18.Supplement_1.S79","article-title":"Measuring the functional impact of fatigue: initial validation of the fatigue impact scale","volume":"18","author":"Fisk","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2026.03.038_bib164","series-title":"ECDEU assessment manual for psychopharmacology. Rev. ed","author":"Guy","year":"1976"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib165","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib166","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.038_bib167","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s43441-024-00693-8","article-title":"Framework for the use and likelihood of regulatory acceptance of single-arm trials","volume":"58","author":"Subramaniam","year":"2024","journal-title":"Ther Innov Regul Sci."},{"issue":"1","key":"10.1016\/j.jhep.2026.03.038_bib168","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/1078-0432.CCR-21-2639","article-title":"Real-world evidence in support of oncology product registration: a systematic review of new drug application and biologics license application approvals from 2015\u20132020","volume":"28","author":"Arondekar","year":"2022","journal-title":"Clin Cancer Res."}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:39:59Z","timestamp":1787380799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826001935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":168,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0168827826001935"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.038","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for the Study of the Liver and American Association for the Study of Liver Diseases. Published by Elsevier BV on behalf of European Association for the Study of the Liver and by Wolters Kluwer Health on behalf of American Association for the Study of Liver Diseases. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}